Jun 07,2017

Medtronic Initiates U.S. Launch of World's First Hybrid Closed Loop System for Type 1 Diabetes

Medtronic plc (NYSE:MDT), today announced the U.S. launch of the MiniMed(TM) 670G system - the world's first Hybrid Closed Loop system for people with type 1 diabetes. The system also exclusively features the CONTOUR®NEXT LINK 2.4 blood glucose monitoring system (BGMS) from Ascensia Diabetes Care.

PRODUCT

#closed loop

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 10,2017

SCIENTIFIC STUDIES ADDRESSING BGMS AND CGM ACCURACY PRESENTED AT THE AMERICAN DIABETES ASSOCIATION'S 77TH SCIENTIFIC SESSIONS

This week at the American Diabetes Association 77th Scientific Sessions, data were presented from three studies that assessed the accuracy and analytical performance of blood glucose monitoring systems (BGMS) and continuous glucose monitoring (CGM) systems. Posters from two investigator initiated studies presented the accuracy data of various BGMS, while another poster, presented by Ascensia, described a new method for evaluating the analytical performance of CGM systems.

CLINICAL STUDY

#bgm

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 12,2017

Nemaura Medical Inc. reports major improvement in sugarBEAT® sensor performance

Nemaura Medical Inc. (OTCBB: NMRD), a medical device company announced the latest version of the sensor component of it’s sugarBEAT® non-invasive wireless skin-patch has achieved a more than 300% improvement in glucose detection. This major improvement is expected to enhance sugarBEAT® accuracy as expressed through MARD, by enabling diabetics to better detect small fluctuations in glucose levels, and for sugarBEAT® to detect glucose at very low levels.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 12,2017

Tandem Diabetes Care Presents Findings from Predictive Low Glucose Suspend (PLGS) Feasibility Study and Announces Approval of Investigational Device Exemption (IDE) for Pivotal Trial

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today presented results from a feasibility study for its predictive low glucose suspend (PLGS) algorithm, designed to suspend insulin delivery when low blood sugar is predicted.

CLINICAL STUDY

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 17,2017

Abbott, Bigfoot Biomedical collaborate on diabetes technologies

Abbott and Bigfoot Biomedical have entered into an agreement to develop and commercialize diabetes management systems, integrating Abbott's FreeStyle Libre glucose sensing technology with Bigfoot's insulin delivery solutions. Under the agreement, Abbott will supply glucose measurement sensors for all of Bigfoot's insulin delivery systems in the U.S. as the exclusive sensors for those systems. Bigfoot, meanwhile, will develop and commercialize multiple systems using Abbott's FreeStyle Libre sensor technology -- including systems designed to perform auto-titration for Bigfoot's connected insulin injection devices -- as well as automated insulin delivery using Bigfoot's insulin infusion platform.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Jul 20,2017

Nemaura Signs Letter of Intent for Licensing Agreement with TPM for GCC Region

Nemaura Medical Inc. (OTCQB: NMRD), a medical technology company focused on the development and commercialization of sugarBEAT®, a wireless disposable adhesive skin-patch for adjunctive use by diabetics as a non-invasive and needle-free continuous glucose monitoring (CGM) system announced today it has signed a non-binding letter of intent with The Principals MENA DMCC (“TPM”) for an exclusive license to market and sell sugarBEAT® in the Gulf Co-operation Council region (“GCC Region”), which consists of Bahrain, Kuwait, Qatar, Saudi Arabia, Oman and United Arab Emirates.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 21,2017

In study, Dexcom finds CGMs can benefit Type 2 patients, too

A new study published today in Annals of Internal Medicine and sponsored by Dexcom shows that a continuous glucose monitor could lower the HbA1c scores of people with Type 2 diabetes, and that acceptance of the technology is high among that group as well.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 01,2017

Nemaura Develops Rechargeable Transmitter for sugarBEAT®

Nemaura Medical Inc. (OTCQB: NMRD), a medical technology company focused on the development and commercialization of sugarBEAT®, announced today that it has developed a slimmer sugarBEAT® transmitter with a built in rechargeable battery. This new format is expected to lower costs for users given it removes the need for disposable batteries.

PRODUCT

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 01,2017

CGM study: Glucose-lowering effect of whey protein depends upon clinical characteristics of patients with type 2 diabetes

This is the first study to investigate glucose response to Whey protein (WP) using continuous glucose monitoring (CGM) over several days. Glucose response to WP was found to be variable but predictable. Lower body mass index, triglyceride and glucagon-like peptide (GLP)-1 predicted glucose lowering, whereas obesity, hypertriglyceridemia and high fasting GLP-1 concentrations predicted increased glucose response to WP.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 15,2017

Nemaura Signs Heads of Terms for sugarBEAT® with Device Technologies for Australia and New Zealand

Nemaura Medical Inc., a medical technology company focused on the development and commercialization of sugarBEAT® announced today it has signed a non-binding term sheet with Device Technologies for exclusive rights to market and sell sugarBEAT® in Australia and New Zealand. Nemaura Medical expect to launch in Australia and New Zealand in 2018, following an anticipated initial launch in UK in 2017.

COLLABORATION PARTNERSHIP

#institution

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM